Les publications 2017

Mir, O ; Penel, N
Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib-hype or me-too?

Pasquier, D ; Nickers, P ; Peiffert, D ; Maingon, P ; Pommier, P ; Lacornerie, T & al
Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
PLoS One, 2017, 12, e0187794

Le Rhun, E ; Bertrand, N ; Dumont, A ; Tresch, E ; Le Deley, MC ; Mailliez, A & al
Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
Eur J Cancer, 2017, 87, 189-198

Azaïs, H ; Ghesquière, L ; Petitnicales, C ; Borghesi, Y ; Tresch-Bruneel, E ; Cordoba, A & al
Pretherapeutic staging of locally advanced cervical cancer: Infraomesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy.
Gynecol Oncol, 2017, 147, 340-344

Penel, N ; Le Cesne, A ; Bonvalot, S ; Giraud, A ; Bompas, E ; Rios, M & al
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group.

Bresson, L ; Leblanc, E ; Lemaire, AS ; Okitsu, T ; Chai, F
Autologous peritoneal grafts permit rapid reperitonealization and prevent postoperative abdominal adhesions in an experimental rat study.
Surgery, 2017, 162, 863-870

Berry, V ; Basson, L ; Bogart, E ; Mir, O ; Blay, JY ; Italiano, A & al
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Cancer, 2017, 123, 2294-2302

Lebellec, L ; Chauffert, B ; Blay, JY ; Le Cesne, A ; Chevreau, C ; Bompas, E & al

Omer, N ; Le Deley, MC ; Piperno-Neumann, S ; Marec-Berard, P ; Italiano, A ; Corradini, N & al
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.

Blay, JY ; Soibinet, P ; Penel, N ; Bompas, E ; Duffaud, F ; Stoeckle, E & al
Improved survival using specialized multidisciplinary board in sarcoma patients.
Ann Oncol, 2017, 28, 2852-2859
Kotecki, N; Penel, N; Awada, A
How to emerge from the conservatism in clinical research methodology?
Curr Opin Oncol, 2017, 29, 400-404

Wagner, A; Crop, F; Mirabel, X; Taill, C; Reynaert, N
Use of an in-house Monte Carlo platform to assess the clinical impact of algorithm-related dose differences on DVH constraints.
Phys Med, 2017, 42, 319-326

Tabone, MD; Brugière, L; Piperno-Neumann, S; Selva, MA; Marec-Bérard, P; Pacquement, H & al
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
BMC Cancer, 2017, 17, 419

Leroy, T; Lacornerie, T; Bogart, E; Nickers, P; Lartigau, E; Pasquier, D
Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center.
Radiat Oncol, 2017, 12, 95

Boydev, C; Demol, B; Pasquier, D; Saint-Jalmes, H; Delpon, G; Reynaert, N
Zero echo time MRI-only treatment planning for radiation therapy of brain tumors after resection.
Phys Med, 2017, 42, 332-338

Penel, N; Chibon, F; Salas, S
Adult desmoid tumors: biology, management and ongoing trials.
Curr Opin Oncol, 2017, 29, 268-274

Lebredonchel, S; Lacornerie, T; Rault, E; Wagner, A; Reynaert, N; Crop, F
About the non-consistency of PTV-based prescription in lung.

Sudour-Bonnange, H; Faure-Conter, C; Martelli, H; Hameury, F; Fresneau, B; Orbach, D & al
Primary mediastinal and retroperitoneal malignant germ cell tumors in children and adolescents: Results of the TGM95 trial, a study of the French Society of Pediatric Oncology (Société Française des Cancers de l'Enfant).
Pediatr Blood Cancer, 2017, 64(9)

Kakkos, A; Bresson, L; Hudry, D; Cousin, S; Lervat, C; Bogart, E & al
Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients.
Eur J Surg Oncol, 2017, 43, 689-695

Deneuve, S; Bodard, AG; Delquignies, E; Janot, F; Zrounba, P; Julieron, M

Bahleda, R; Le Deley, MC; Bernard, A; Chaturvedi, S; Hanley, M; Poterie, A & al
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Invest New Drugs, 2017
Buonadonna, A ; Benson, C ; Casanova, J ; Kasper, B ; López Pousa, A ; Mazzeo, F & al
A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma.
Anticancer Drugs, 2017, 28, 1157-1165

Sadowski, SM ; Cadiot, G ; Dansin, E ; Goudet, P ; Triponez, F
The future: surgical advances in MEN1 therapeutic approaches and management strategies.
Endocr Relat Cancer, 2017, 24, T243-T260

Petitinicos, C ; Azais, H ; Ghesquière, L ; Tresch-Bruneel, E ; Cordoba, A ; Narducci, F & al
Morbidity of Staging Inframesenteric Paraortic Lymphadenectomy in Locally Advanced Cervical Cancer Compared With Infrarenal Lymphadenectomy.
Int J Gynecol Cancer, 2017, 27, 575-580

Fresneau, B ; Hackshaw, A ; Hawkins, DS ; Paulussen, M ; Anderson, JR ; Judson, I & al
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Pediatr Blood Cancer, 2017, 64(8)

Bosc, R ; Hersant, B ; Carloni, R ; Niddam, J ; Bouhassira, J ; De Kermadec, H & al
Mandibular reconstruction after cancer: an in-house approach to manufacturing cutting guides.

Vennin, C ; Spruyt, N ; Robin, YM ; Chassat, T ; Le Bourhis, X ; Adriaenssens, E
The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.

Cordoba, A ; Escande, A ; Comte, P ; Fumagalli, I ; Bresson, L ; Mubiayi, N & al
Locally advanced adenocarcinoma of the cervix on uterus didelphys: a case report.
J Contemp Brachytherapy, 2017, 9, 71-76

Duprez, C ; Vanlemmens, L ; Untas, A ; Antoine, P ; Lesur, A ; Loustalot, C & al
Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.
Future Oncol, 2017, 13, 2667-2680

Collange, O ; Garcia, V ; Kindo, M ; Meyer, N ; Lavaux, T ; Mertes, PM & al
Comparison of capillary and arterial lactate levels in patients with shock.

Bailey, HD ; Lacour, B ; Guerrini-Rousseau, L ; Bertozzi, AI ; Leblond, P ; Faure-Conte, C & al
Parental smoking, maternal alcohol, coffee and tea consumption and the risk of childhood brain tumours: the ESTELLE and ESCALE studies (SFCE, France).
Cancer Causes Control, 2017, 28, 719-732

Houvenaeghel, G ; Lambaudie, E ; Cohen, M ; Classe, JM ; Reyal, F ; Garbay, JR & al
Therapeutic escalation - De-escalation: Data from 15,508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
Breast, 2017, 34, 24-33
Dezellus, A ; Barriere, P ; Campone, M ; Lemanski, C ; Vanlemmens, L ; Mignot, L & al
Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.

Furet, E ; El Bouchtaoui, M ; Feugeas, JP ; Miquel, C ; Leboeuf, C ; Beytout, C & al
Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes.
Oncotarget, 2017, 8, 37332-37341

Duruisseaux, M ; Besse, B ; Cadranel, J ; Pérol, M ; Menneecier, B ; Bigay-Game, L & al
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Oncotarget, 2017, 8, 21903-21917

Dauplat, J ; Kwiatkowski, F ; Rouanet, P ; Delay, E ; Clough, K ; Verhaeghe, JL & al
Quality of life after mastectomy with or without immediate breast reconstruction.

Chiannilkulchai, N ; Pautier, P ; Genestie, C ; Bats, AS ; Vacher-Lavenu, MC ; Devouassoux-Shisheboran, M & al
Networking for ovarian rare tumors: a significant breakthrough improving disease management.
Ann Oncol, 2017, 28, 1274-1279

Boisdron-Celle, M ; Metges, JP ; Capitain, O ; Adenis, A ; Raoul, JL ; Lecomte, T & al
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Semin Oncol, 2017, 44, 24-33

Turpin, A ; Pauquier, D ; Massard, C ; Berdah, JF ; Culiné, S ; Penel, N
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Bull Cancer, 2017, 104, 552-558

Massard, C ; Michiels, S ; Ferté, C ; Le Deley, MC ; Lacroix, L ; Hollebecque, A & al
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Cancer Discov, 2017, 7, 586-595

Twelves, C ; Cortés, J ; O'Shaughnessy, J ; Awada, A ; Perez, EA ; Im, SA & al
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial.


Bendifallah, S ; Perrin, M ; Ouldamer, L ; Lavoué, V ; Canlorbe, G ; Raimond, E & al
Honing the classification of high-risk endometrial cancer with inclusion of lymphovascular space invasion.
Surg Oncol, 2017, 26, 1-7
Vera, P ; Thureau, S ; Chaumet-Riffaud, P ; Modzelewski, R ; Bohn, P ; Vermandel, M & al
F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).

Markar, SR ; Gronnier, C ; Pasquer, A ; Duhamel, A ; Behal, H ; Théreaux, J & al
Surgically treated oesophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes.
Eur J Cancer, 2017, 75, 179-189

Stacchiotti, S ; Gronchi, A ; Fossati, P ; Akiyama, T ; Alapetite, C ; Baumann, M & al
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.
Ann Oncol, 2017, 28, 1230-1242

Pierga, JY ; Bidard, FC ; Autret, A ; Petit, T ; Andre, F ; Dalenc, F & al
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Ann Oncol, 2017, 28, 103-109

de Nonneville, A ; Gonçalves, A ; Zemmour, C ; Classe, JM ; Cohen, M ; Lambaudie, E & al
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

Veldhuijzen van Zanten, SE ; Baugh, J ; Chaney, B ; De Jongh, D ; Sanchez Aliaga, E ; Barkhof, F & al
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease.
J Neurooncol, 2017, 132, 255-266

Classe, M ; Malouf, GG ; Su, X ; Yao, H ; Thompson, EJ ; Doss, DJ & al
Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Histopathology, 2017, 70, 1089-1097

Tensaouti, F ; Ducassou, A ; Chaltiel, L ; Bolle, S ; Muracciole, X ; Coche-Dequeant, B & al
Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma.
Radiother Oncol, 2017, 122, 362-367

Heudel, PE ; Fabbro, M ; Roemer-Becuwe, C ; Kaminsky, MC ; Arnaud, A ; Joly, F & al
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Br J Cancer, 2017, 116, 303-309

Gorphe, P ; Von Tan, J ; El Bedoui, S ; Hartl, DM ; Auperin, A ; Qassemeyer, Q & al
Early assessment of feasibility and technical specificities of transoral robotic surgery using the da Vinci Xi.
J Robot Surg, 2017, 11, 455-461
Bailey, HD; Rios, P; Lacour, B; Guerrini-Rousseau, L; Bertozi, AI; Leblond, P & al
Factors related to pregnancy and birth and the risk of childhood brain tumours: The ESTELLE and ESCALE studies (SFCE, France).
Int J Cancer, 2017, 140, 1757-1769

Baldini, C; Escande, A; Bouché, O; El Hajbi, F; Volet, J; Bourgeois, V & al
Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
Pancreatology, 2017, 17, 146-149

Bell, R; Brown, J; Parmar, M; Toi, M; Suter, T; Steger, GG & al
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Ann Oncol, 2017, 28, 754-760

Risoud, M; Mortuaire, G; Leroy, X; Leblond, P; Fayoux, P
Desmoid tumours of the head and neck in children: Review of management.

Stern, N; Sakji, I; Defachelles, AS; Lervat, C; Ryckewaert, T; Marliot, G & al
[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Bull Cancer, 2017, 104, 208-212

Mok, TS; Wu, Y-L; Ahn, M-J; Garassino, MC; Kim, HR; Ramalingam, SS & al
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Cecchetto, G; Ganarin, A; Bien, E; Vorwerk, P; Bisogno, G; Godzinski, J & al
Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: A report from the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT).
Pediatr Blood Cancer, 2017, 64(6)

Rouzier, R; Gouy, S; Selle, F; Lambaudie, E; Floquet, A; Fourchotte, V & al
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Eur J Cancer, 2017, 70, 133-142

Ducréux, M; Bennouna, J; Adenis, A; Conroy, T; Lièvre, A; Portales, F & al
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.
Cancer Chemoth Pharmacol, 2017, 79, 9-16

Hochart, A; Leblond, P; Le Bourhis, X; Meignan, S; Tulasne, D
[MET receptor inhibition: Hope against resistance to targeted therapies?]
Bull Cancer, 2017, 104, 157-166

Dalenc, F; Penault-Llorca, F; Cohen, M; Houvenaeghel, G; Piat, JM; Liegeois, P & al
Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
Karam, I ; Yao, M ; Heron, DE ; Poon, I ; Koyfman, SA ; Yom, SS & al
Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future Oncol, 2017, 13, 603-613

Quanico, J ; Franck, J ; Cardon, T ; Leblanc, E ; Wisztorski, M ; Salzet, M & al
NanoLC-MS coupling of liquid microjunction microextraction for on-tissue proteomic analysis. Biochim Biophys Acta, 2017, 1865, 891-900

Dassonville, O ; Bozec, A ; Château, Y ; Reyt, E ; Devauchelle, B ; Louis, MY & al

Laborde, A ; Nicot, R ; Wojcik, T ; Ferri, J ; Raoul, G

Brard, C ; Le Teuff, G ; Le Deley, MC ; Hampson, LV
Bayesian survival analysis in clinical trials: What methods are used in practice? Clin Trials, 2017, 14, 78-87

Dupont, B ; Mariotte, D ; Dugué, AE ; Clarisse, B ; Grellard, JM ; Babin, E & al

Cordoba, A ; Escande, A ; Leroy, T ; Mirabel, X ; Coche-Dequéant, B ; Lartigau, E

Moreno, L ; Rubie, H ; Varo, A ; Le Deley, MC ; Amoroso, L ; Chevance, A & al

Reich, M ; Girard, E ; Le Rhun, E
Breast leptomeningeal metastasis recurrence presenting as a manic episode. Palliat Support Care, 2017, 15, 272-275

Castela, A ; Gomes, P ; Silvestre, R ; Guardão, L ; Leite, L ; Chilro, R & al

Cougnenc, O ; Defachelles, AS ; Carpentier, P ; Lervat, C ; Clisant, S ; Oudoux, A & al

Chalavon, E ; Lampin, ME ; Lervat, C ; Leroy, X ; Bonnevalle, M ; Recher, M & al
Dilated Cardiomyopathy Caused by Wilms Tumor. Pediatr Emerg Care, 2017, 33, 41-42
Adenis, A; Piessen, G; Azria, D
Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence?
Ann Transl Med, 2017, 5, 503

Baldacci, S; Mazieres, J; Tomasiní, P; Girard, N; Guisier, F; Audigier-Valette, C & al
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.
Oncotarget, 2017, 8, 105103-105114

Rochezfort, P; Italiano, A; Laurence, V; Penel, N; Lardy-Cleaud, A; Mir, O & al
A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome.
Sci Rep, 2017, 7, 17917

Perret, G; Lacornerie, T; Manca, F; Giordano, S; Kumemura, M; Lafitte, N & al
[Measure of the biomechanical degradation of a DNA fiber under the influence of therapeutic X-rays].

Houvenaeghel, G; Quilichini, O; Cohen, M; Reyal, F; Classe, JM; Mazouni, C & al
Sentinel lymph node biopsy validation for large tumors.

Martin, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H & al
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol, 2017, 18, 1688-1700

Jobard, E; Trédan, O; Bachelot, T; Vigneron, AM; Aït-Oukhatar, CM; Arnedos, M & al
Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.
Oncotarget, 2017, 8, 83570-83584

Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P & al
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Jannin, A; Hennart, B; Adenis, A; Chauffert, B; Penel, N
Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.

Paris, C; Do, P; Mastroianni, B; Dixmier, A; Dumont, P; Pichon, E & al
Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Eur Respir J, 2017, 50(4)

Fizazi, K; Ulys, A; Sengeløv, L; Moe, M; Ladoire, S; Thiery-Vuillemin, A & al
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Ann Oncol, 2017, 28, 2741-2746
Habraken, SJM ; Sharfo, AWM ; Buijsen, J ; Verbakel, WFAR ; Haasbeek, CJA ; Öllers, MC & al
The TRENDY multi-center randomized trial on hepatocellular carcinoma - Trial QA including automated treatment planning and benchmark-case results. Radiother Oncol, 2017, 125, 507-513

Renault, AL ; Mebiroouk, N ; Cavaciuti, E ; Le Gal, D ; Lecarpentier, J ; d’Enghien, CD & al
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. Carcinogenesis, 2017, 38, 994-1003

Azria, D ; Doyen, J ; Jarlier, M ; Martel-Lafay, I ; Hennequin, C ; Etienne, P & al
Late toxicities and clinical outcome at 5?years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol, 2017, 28, 2436-2442

Cohen, EEW ; Licitra, LF ; Burtness, B ; Fayette, J ; Gaurier, T ; Clement, PM & al

Kasper, B ; Baumgarten, C ; Garcia, J ; Bonvalot, S ; Haas, R ; Haller, F & al

Gomez-Brouchet, A ; Illac, C ; Gilhodes, J ; Bouvier, C ; Aubert, S ; Guinebretiere, JM & al
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. Oncoimmunology, 2017, 6, e1331193

Le Rhun, E ; Weller, M ; Brandsma, D ; Van den Bent, M ; de Azambuja, E ; Henriksson, R & al

Bibault, JE ; Dussart, S ; Pommier, P ; Morelle, M ; Huguet, M ; Boisselier, P & al

Vallières, M ; Kay-Rivest, E ; Perrin, LJ ; Liem, X ; Furstoss, C ; Aerts, HJWL & al

Joensuu, H ; Blay, JY ; Comandone, A ; Martin-BROTO, J ; Fumagalli, E ; Grignani, G & al
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Br J Cancer, 2017, 117, 1278-1285
Lacornerie, T ; Rio, E ; Mahé, MA
[Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses].
Cancer Radiother, 2017, 21, 574-579

Kim, S ; Jary, M ; André, T ; Vendrely, V ; Buecher, B ; François, E & al
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
BMC Cancer, 2017, 17, 574

Rios, P ; Bailey, HD ; Lacour, B ; Valteau-Couanet, D ; Michon, J ; Bergeron, C & al
Maternal use of household pesticides during pregnancy and risk of neuroblastoma in offspring. A pooled analysis of the ESTELLE and ESCALE French studies (SFCE).
Cancer Causes Control, 2017, 28, 1125-1132

Salas, S ; Resseguier, N ; Blay, JY ; Le Cesne, A ; Italiano, A ; Chevreau, C & al

Bascoul-Mollevi, C ; Gourou, S ; Galais, MP ; Raoul, JL ; Bouché, O ; Douillard, JY & al
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Eur J Cancer, 2017, 84, 239-249

Delaunay, M ; Cadranel, J ; Lusque, A ; Meyer, N ; Gounant, V ; Moro-Sibilot, D & al
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
Eur Respir J, 2017, 50(5)

de Nonneville, A ; Gonçalves, A ; Zemmour, C ; Cohen, M ; Classe, JM ; Reyal, F & al
Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
Eur J Cancer, 2017, 84, 34-43

Basse, C ; Thureau, S ; Bota, S ; Dansin, E ; Thomas, PA ; Pichon, E & al
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.
J Thorac Oncol, 2017, 12, 1715-1722

Massard, C ; Borget, I ; Farace, F ; Aspeslagh, S ; Le Deley, MC ; Le Tourneau, C & al
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.
Eur J Cancer, 2017, 83, 185-193

Mesdag, V ; Régis, C ; Tresch, E ; Chauvet, MP ; Boulanger, L ; Collinet, P & al
Nipple sparing mastectomy for breast cancer is associated with high patient satisfaction and safe oncological outcomes.
J Gynecol Obstet Hum Reprod, 2017, 46, 637-642
Yang, JC ; Ou, SI ; De Petris, L ; Gadgeel, S ; Gandhi, L ; Kim, DW & al
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
J Thorac Oncol, 2017, 12, 1552-1560

Guckenberger, M ; Andratschke, N ; Dieckmann, K ; Hoogeman, MS ; Hoyer, M ; Hurkmans, C & al
ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer.
Radiother Oncol, 2017, 124, 11-17

Siegfried, A ; Morin, S ; Munzer, C ; Delisle, MB ; Gambart, M ; Puget, S & al
A French retrospective study on clinical outcome in 102 choroid plexus tumors in children.

Gnekow, AK ; Walker, DA ; Kandels, D ; Picton, S ; Giorgio Perilongo, ; Grill, J & al
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (<16 years) low grade glioma - A final report.
Eur J Cancer, 2017, 81, 206-225

Lemelle, L ; Pierron, G ; Fréneaux, P ; Huybrechts, S ; Spiegel, A ; Plantaz, D & al
NUT carcinoma in children and adults: A multicenter retrospective study.
Peditr Blood Cancer, 2017, 64(12)

Pautier, P ; Kalbacher, E ; de la Motte Rouge, T ; Bonnetain, F ; Lesoin, A
Cancer de l’ovaire : la rechute précoce
Bull Cancer, 2017, 104 Suppl 1, S32-S38

Hollebecque, A ; Bahleda, R ; Faivre, L ; Adam, J ; Poinsignon, V ; Paci, A & al
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.
Eur J Cancer, 2017, 81, 81-89

Cortés, J ; Rugo, HS ; Awada, A ; Twelves, C ; Perez, EA ; Im, SA & al
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Rullier, E ; Rouanet, P ; Tuch, JJ ; Valverde, A ; Lelong, B ; Rivoire, M & al
Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Lancet, 2017, 390, 469-479

Demoor-Goldschmidt, C ; Drui, D ; Doutriaux, I ; Michel, G ; Auquier, P ; Dumas, A & al
A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
BMC Cancer, 2017, 17, 326

Etienne-Grimaldi, MC ; Boyer, JC ; Beroud, C ; Mbatchi, L ; van Kuilenburg, A ; Bobin-Dubigeon, C & al
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
PLoS One, 2017, 12, e0175998
Renaud, F ; Bibeau, F ; Leteurtre, E ; Delaeter, C ; Dib, M ; Harter, V & al
[FREGAT: French clinico-biological database dedicated to esogastric cancers].
Ann Pathol, 2017, 37, 457-466

Durand, B ; Zairi, F ; Boulander, T ; Bonneterre, J ; Mortier, L ; Le Rhun, E
Chemical meningitis related to intra-CSF liposomal cytarabine.
CNS Oncol, 2017, 6, 261-267

Delcourt, V ; Franck, J ; Leblanc, E ; Narducci, F ; Robin, YM ; Gimeno, JP & al
Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer.
EBioMedicine, 2017, 21, 55-64

Gryseleyn, R ; Schlund, M ; Pigache, P ; Wojcik, T ; Raoul, G ; Ferri, J
Influence of preoperative imaging on fibula free flap harvesting.

Pougnet, I ; Jaegle, E ; Garcia, R ; Tessier, F ; Faivre, JC ; Louvel, G & al
[Spinal stereotactic body radiotherapy: French assessment in 2016].
Cancer Radiother, 2017, 21, 276-285

Vignot, S ; André, T ; Gonçalves, A ; Guièze, R ; Magné, N ; Orbach, D & al
[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].
Bull Cancer, 2017, 104, 6-19

Niu, H ; Shin, H ; Gao, F ; Zhang, J ; Bahamon, B ; Danaee, H & al
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
EBioMedicine, 2017, 25, 50-57